Drug intelligence / Profile preview

MyoVera

Development stage: Unknown
Lead developer: Nutrition21
Modality: Small Molecules
Administration: Oral

Overview

MyoVera is a patented dietary supplement ingredient developed by Nutrition21 for muscle health and strength optimization. It is a proprietary combination of amylopectin and a chromium complex, designed to be used in conjunction with protein supplementation and exercise. The ingredient works by amplifying muscle protein synthesis (MPS) and supporting the uptake of amino acids into muscle tissue, thereby maximizing the body's utilization of protein for muscle growth and repair. Formerly marketed as Velositol, MyoVera is intended for use in various product formats, including powders, beverages, and nutrition bars, to support lean muscle mass development.

Brand names: MyoVeraVelositol
Other names: amylopectin + chromium complex

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on MyoVera.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyoVera.

Explore the full profile